4DMT to receive $85 million upfront cash payment and expect to receive at least $50 million of cost sharing from Otsuka over the next three years for development activities supporting global registration Up to $336 million in potential regulatory and commercial milestones and tiered double-digit royalties depending on net sales in Otsuka’s territoriesProceeds and cost sharing expected to support global Phase 3 clinical trial in DME and pre-commercial activities EMERYVILLE, Calif., Oct. 30, 2025 (GLOBE NEWSW ...